Immunotherapy in the Treatment of Biliary Tract Cancer: The Future?
Article Quality & Performance Metrics
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
Abstract
Biliary tract cancer is known for its dismal prognosis, both due to late diagnosis as well as to the short width span of therapeutic options available. Although much more common in Asian countries, the number of patients with these tumours has been rising in European and American countries, mainly due to the increased rates of chronic hepatic diseases. Currently the only curative treatment revolves around surgical resection, although only possible in roughly 10-15% of patients. First line systemic therapies include chemotherapy with gemcitabine and cisplatin, unfortunately with also poor results with a 5-year survival rate of only 10-20%. With this in mind, the need for other therapeutic options has been proved, with the rising popularity of immunotherapy leading to several studies analysing the use of immune checkpoint inhibitors in the treatment of patients with biliary tract cancer.
| Reference Key |
dl2022immunotherapy
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | DL, Russo |
| Journal | Gastroenterology & Hepatology International Journal |
| Year | 2022 |
| DOI |
10.23880/ghij-16000187
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
ZincirX productsfrom the team behind Journament
-
PatentYazar
Patent drafts for the EPO, USPTO and TürkPatent
From inventor notes to a DOCX draft: description, claims, abstract. The machine drafts, the attorney signs.
See how it works (opens in a new tab) -
Projenator
Have a project idea? Score and plan it with AI
AI scores your idea in five dimensions and builds a phased plan. Your first project is free, no card needed.
Start your first project (opens in a new tab)
Cookies
We use strictly necessary cookies to run the site and keep you signed in. With your permission we would also use Google Analytics to see how the site is used, and Google AdSense to show ads on journal and article pages. Both stay off unless you accept, and you can change your mind at any time. How we use cookies · KVKK notice (Türkiye)
Cookie settings
Comments
No comments yet. Be the first to comment on this article.